To support the establishment of new cancer registries and maintain good quality cancer registries in Africa, by providing access to education, training, research and Mentorship.
21st July 2020 – 29th September 2020
Course Director: Prof. Fredrick Chite Asirwa MD
Consultant Physician. Medical Oncologist & Hematologist
Executive Director/CEO: International Cancer Institute (ICI)
P.O. Box 8088, Code 30100 Eldoret, Kenya
Lead Faculty: Gladys Chesumbai Onyango
IARC-GICR Regional Trainer.
CANREG 5 Consultant: African Cancer Registry Network.
Cancer Registry Coodinator: The Eldoret Cancer Registry.
P.O. Box 4606-30100, Eldoret, KENYA.
IARC-AFCRN Acrredited Faculty
This educational activity is provided by International Cancer Institute (ICI)
This activity is supported by educational grant from BMSF
Each topic takes 2 hours, Interactive Sessions done on Zoom, Course evaluation forms filled by each participant.
Participants should be willing to spend at least 4 hours per week on this online course over a period of 10 weeks. (Duration 40 hours)
All those interested in registration to this course, please send your information to email@example.com
|NO.||MODULE 1 TOPICS||TIME IN HOURS|
|1||Introduction to Cancer Registry||2|
|2||Requirements for Establishing a Cancer Registry||2|
|3||Introduction to Cancer Registration Principles and Methods||2|
|4||Case Finding and Abstraction Overview||2|
|5||Abstracting Personal Information||2|
|6||Abstracting Incident Date & Date of last Contact||2|
|7||Basis of Diagnosis Coding Rules||2|
|8||Abstracting Primary Site and Diagnosis.||2|
|9||Abstracting Treatment Information||2|
|10||ICDO Coding Overview||2|
|11||ICDO Coding Rules||2|
|12||ICDO Coding for Topography||2|
|13||ICDO Coding for Morphology||2|
|14||Multiple primary Rules||2|
|15||Introduction to Staging||2|
|16||Introduction to Essential TNM||2|
|17||Introduction to CanReg5||2|
|19||Principles of Confidentiality and Privacy||2|
|20||Cancer Regisrty Report||2|
ICI acknowledges that the funding for this preceptorship training has been proudly supported by the Bristol-Myers Squibb Foundation (BMSF) Secure the Future Programme.